Moderna stock was one of the worst performers in the S&P 500 last year as Covid-19 vaccine sales tumbled, but the vaccine maker has more to offer, according to Oppenheimer analysts. ...

Stocks have had a banner year, but two Covid-era heroes were left in the dust. Analysts think that could change in 2024. ...

Key Points Industry/Company - **Company**: Moderna, Inc. (NASDAQ:MRNA) - **Industry**: Biotechnology, mRNA medicine Core Points and Evidence - **Mission**: To deliver the greatest possible impact to people through mRNA medicine. - **Platform**: Moderna's mRNA platform allows for the creation of multiple medicines for various diseases. - **Pipeline**: Several medicines in development for 2024 and 2025, including vaccines, cancer, and rare genetic diseases. - **Disease X**: Moderna is preparing for a potential next pandemic with mRNA access, a tool to create an ecosystem for collaboration with scientists worldwide. - **Environmental Goals**: Net zero carbon emissions for Scope 1 and 2 by 2030. - **Employee Focus**: Attracting and retaining top talent, fostering a diverse and inclusive culture, and providing employee benefits and development opportunities. - **Community Engagement**: Employee volunteering programs, philanthropic giving, and partnerships with NGOs. - **Governance and Ethics**: Strong governance practices, ethical business conduct, and transparency in ESG reporting. Other Important Points - **Rare Diseases**: Moderna's mRNA platform has shown promise in treating rare diseases, with several programs demonstrating positive results. - **Health Equity**: Moderna is committed to inclusive research and ensuring that clinical trials represent diverse populations. - **Pandemic Preparedness**: Moderna's mRNA platform has been instrumental in developing the COVID-19 vaccine and is being used to prepare for future pandemics. - **Global Health Portfolio**: Includes vaccines for COVID-19, Zika, Chikungunya, HIV, and pandemic influenza. - **mRNA Access Program**: Collaborates with academic institutions worldwide to develop mRNA vaccines against emerging and neglected infectious diseases. - **Sustainability**: Moderna is committed to sustainability by design, resource conservation, and decarbonizing its value chain. - **Employee Engagement**: Moderna focuses on employee engagement, culture, and well-being through various programs and initiatives. - **Community Impact**: Moderna's community programs focus on education, health, and social justice. - **Governance**: Moderna's board of directors and executive committee are committed to ESG oversight and accountability. References - [doc id='3'] - [doc id='5'] - [doc id='7'] - [doc id='8'] - [doc id='9'] - [doc id='10'] - [doc id='12'] - [doc id='13'] - [doc id='14'] - [doc id='15'] - [doc id='16'] - [doc id='17'] - [doc id='18'] - [doc id='19'] - [doc id='20'] - [doc id='21'] - [doc id='22'] - [doc id='23'] - [doc id='24'] - [doc id='25'] - [doc id='26'] - [doc id='27'] - [doc id='28'] - [doc id='29'] - [doc id='30'] - [doc id='31'] - [doc id='32'] - [doc id='33'] - [doc id='34'] - [doc id='35'] - [doc id='36'] - [doc id='37'] - [doc id='38'] - [doc id='39'] - [doc id='40'] - [doc id='41'] - [doc id='42'] - [doc id='43'] - [doc id='44'] - [doc id='45'] - [doc id='46'] - [doc id='47'] - [doc id='48'] - [doc id='49'] - [doc id='50'] - [doc id='51'] - [doc id='52'] - [doc id='53'] - [doc id='54'] - [doc id='55'] - [doc id='56'] - [doc id='57'] - [doc id='58'] - [doc id='59'] - [doc id='60'] - [doc id='61'] - [doc id='62'] - [doc id='63'] - [doc id='64'] - [doc id='65'] - [doc id='66'] - [doc id='67'] - [doc id='68'] - [doc id='69'] - [doc id='70'] - [doc id='71'] - [doc id='72'] - [doc id='73'] - [doc id='74'] - [doc id='75'] - [doc id='76'] - [doc id='77'] - [doc id='78'] - [doc id='79'] - [doc id='80'] - [doc id='81'] - [doc id='82'] - [doc id='83'] - [doc id='84'] - [doc id='85'] - [doc id='86'] - [doc id='87'] - [doc id='88'] - [doc id='89'] - [doc id='90'] - [doc id='91'] - [doc id='92'] - [doc id='93'] - [doc id='94'] - [doc id='95'] - [doc id='96'] - [doc id='97'] - [doc id='98'] - [doc id='99'] - [doc id='100'] - [doc id='101'] - [doc id='102'] - [doc id='103'] - [doc id='104'] - [doc id='105'] - [doc id='106'] - [doc id='107'] - [doc id='108'] - [doc id='109'] - [doc id='110'] - [doc id='111'] - [doc id='112'] - [doc id='113'] - [doc id='114'] - [doc id='115'] - [doc id='116'] - [doc id='117'] - [doc id='118'] - [doc id='119'] - [doc id='120'] - [doc id='121'] - [doc id='122'] - [doc id='123'] - [doc id='124'] - [doc id='125'] - [doc id='126'] - [doc id='127']

Moderna, Inc. (NASDAQ:MRNA) 2023 Jefferies London Healthcare Conference November 16, 2023 3:30 AM ET Company Participants Lavina Talukdar - Senior Vice president of Investor Relations Unidentified Analyst Good morning everyone. Thank you for joining us here on our opening morning session for Moderna. Up here with me on the stage I have Senior Vice president of Investor Relations, Lavina Talukdar. Lavina, I would love to just maybe start coming away from third quarter earnings. The company provided some new ...

Moderna, Inc. (NASDAQ:MRNA) Second Digital Investor Event November 8, 2023 8:00 AM ET Company Participants Lavina Talukdar - Head of IR Stephane Bancel - CEO Brad Miller - Chief Information Officer Dave Johnson - Chief Data and Artificial Intelligence Officer Wenhao Liu - Director of Software Engineering Brice Challamel - Empowerment VP Conference Call Participants Hartaj Singh - Oppenheimer & Co. Jasmine Fels - UBS Jessica Fye - JP Morgan Lavina Talukdar Good morning, everyone, and welcome to Moderna's Se ...

Moderna, Inc. (NASDAQ:MRNA) Q3 2023 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Lavina Talukdar - Head of Investor Relations St??phane Bancel - Chief Executive Officer Arpa Garay - Chief Commercial Officer Jamey Mock - Chief Financial Officer Stephen Hoge - President Conference Call Participants Gena Wang - Barclays Salveen Richter - Goldman Sachs Terence Flynn - Morgan Stanley Jessica Fye - JPMorgan Luca Issi - RBC Capital Hartaj Singh - Oppenheimer Evan Wang - Guggenheim Secu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _ to _ Commission File Number: 001-38753 Moderna, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 81-3467528 (State or Other Jurisdicti ...

© 2023 Moderna, Inc. All rights reserved. © 2023 Moderna, Inc. All rights reserved. Business Review Stéphane Bancel, CEO © 2023 Moderna, Inc. All rights reserved. COVID product (Spikevax) sales Increasing Spikevax share in the current season1 Resizing manufacturing footprint to accelerate gross margin expansion toward longer-term target of 75-80% 4 © 2023 Moderna, Inc. All rights reserved. Commercial Market Arpa Garay, CCO Looking Forward Stéphane Bancel, CEO 3Q23 Spikevax sales of $1.8B; updating sales out ...

Summary of Moderna, Inc. R&D Day and Business Updates (September 13, 2023) Company Overview - **Company**: Moderna, Inc. (NASDAQ:MRNA) - **Participants**: Key executives including CEO Stephane Bancel, President Stephen Hoge, and others involved in various therapeutic areas and vaccine programs [2][4] Core Industry Insights - **Industry**: Biotechnology and Pharmaceuticals, focusing on mRNA technology for vaccines and therapeutics - **Key Focus Areas**: Infectious diseases, cancer therapeutics, rare diseases, and vaccine development Key Points and Arguments 1. **Platform Technology**: Moderna's mRNA technology is viewed as a powerful platform for developing a new class of medicines, allowing for high productivity in R&D and capital efficiency [4][5][6][7] 2. **Product Pipeline**: The company aims to launch up to 15 products in the next five years, with a focus on infectious disease vaccines, cancer therapeutics, and rare diseases [12][29] 3. **Positive Phase 3 Data**: Moderna has achieved positive Phase 3 data for COVID-19, RSV, and flu vaccines, demonstrating the effectiveness of its platform [9][19] 4. **Cancer Therapeutics**: The company is advancing its individualized neoantigen therapy for melanoma and has plans for accelerated approval discussions based on promising data [10][15][31] 5. **Vaccine Development**: Moderna is working on next-generation COVID vaccines and combination vaccines (COVID + flu), with clinical data expected soon [13][38] 6. **Regulatory Approvals**: The company has received FDA approval for its updated COVID vaccine and is in discussions for its flu vaccine [44][60] Additional Important Content 1. **Investment in Science**: Moderna emphasizes continuous investment in scientific research to expand the capabilities of its mRNA platform [8][22] 2. **Diverse Applications**: The company is exploring various applications in oncology and rare diseases, including partnerships for gene editing technologies [26][27][23] 3. **Clinical Trials**: Ongoing clinical trials are crucial for validating the safety and efficacy of new vaccines and therapeutics, with a focus on both adult and pediatric populations [39][63] 4. **Monitoring Variants**: Moderna has established a robust process for monitoring COVID-19 variants and updating vaccines accordingly, ensuring continued efficacy against emerging strains [45][56] 5. **Safety Profiles**: The safety profiles of new vaccines are being closely monitored, with data showing acceptable reactogenicity compared to standard vaccines [63][64] Conclusion Moderna is positioned as a leader in the biotechnology sector, leveraging its mRNA platform to develop a wide range of vaccines and therapeutics. The company is focused on expanding its product pipeline, achieving regulatory approvals, and continuously improving its technology to meet public health needs.

Moderna, Inc. (NASDAQ:MRNA) Morgan Stanley 21st Annual Global Healthcare Conference September 12, 2023 12:15 PM ET Company Participants Stephane Bancel - CEO Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Great. Well, good afternoon, everybody. Thanks for joining us. I???m Terence Flynn, the U.S. biopharm analyst at Morgan Stanley. We???re very pleased to be hosting Moderna this afternoon. We have Stephane Bancel, who is the Company???s CEO, Stephane, thanks so much for being here ...